Ophthalmic Drugs Market Is Estimated To Witness High Growth Owing To Opportunity In Treating Eye Disorders

ophthalmic drugs market

 

The ophthalmic drugs market comprises medications that are used to treat various eye disorders such as glaucoma, dry eye, infection/inflammation, retinal disorders, allergies, and others. Ophthalmic drugs are available in various formulations such as solutions, gels, ointments, eye drops, and others to ensure effective drug delivery to the eye. Factors such as the rising prevalence of eye diseases, increasing geriatric population, and growing awareness about eye care are driving the demand for ophthalmic drugs.

The global ophthalmic drugs market is estimated to be valued at US$ 48.19 Bn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

The growing prevalence of eye disorders presents a lucrative market opportunity. It is estimated that around 2.2 billion people worldwide suffer from vision impairment or blindness, with cataracts and glaucoma being the leading causes. Moreover, diabetes is one of the major causes of preventable blindness globally. Approximately 50-60% of diabetic patients develop diabetic retinopathy, which can lead to vision impairment and blindness if not diagnosed and treated timely. Thus, the need for affordable and effective drugs to treat such prevalent eye disorders is increasing rapidly. This presents a significant market opportunity for ophthalmic drug manufacturers to develop and commercialize innovative and cost-effective drugs to cater to this large patient pool suffering from various eye diseases worldwide.

Porter's Analysis

Threat of new entrants: The threat of new entrants in the ophthalmic drugs market is low as substantial capital investment is required to conduct research and development in the industry. Besides, established pharmaceutical companies possess strong brand recognition and distribution networks, which pose barriers for new entrants.

Bargaining power of buyers: The bargaining power of buyers in the ophthalmic drugs market is moderate. While the prevalence of eye diseases provides stable demand, the availability of generic drugs impacts the pricing power of established brands.

Bargaining power of suppliers: Suppliers of active pharmaceutical ingredients and other raw materials face moderate bargaining power as they have to meet stringent quality standards of ophthalmic drugs manufacturers. However, the presence of many suppliers mitigates the threat.

Threat of new substitutes: New substitutes pose a low threat as ophthalmic drugs require extensive clinical validation for efficacy and safety before regulatory approval and market entry. New substitutes may take significant time and capital to displace existing drug brands.

Competitive rivalry: Competitive rivalry in the ophthalmic drugs market is high owing to the presence of numerous global and regional players offering generic and branded formulations. Manufacturers compete based on product differentiation, pricing, and marketing strategies.

SWOT Analysis

Strength: Wide portfolio of innovative drugs, brand recognition, strong distribution network.

Weakness: High research and development costs, price erosion of branded drugs, patent cliffs.

Opportunity: Rising geriatric population, increasing prevalence of eye diseases, emerging markets growth.

Threats: Intense competition from generic drugs, pricing pressures, regulatory hurdles.

Key Takeaways

The global Ophthalmic Drugs Market Demand is expected to witness high growth over the forecast period due to the rising geriatric population which is highly susceptible to various eye conditions. Regionally, North America currently dominates the market due to high healthcare expenditures and presence of major players in the region. The United States represents the largest market for ophthalmic drugs globally.

Regional analysis related content:

North America is expected to retain its leading position in the global ophthalmic drugs market during the forecast period. This is attributable to factors such as advanced healthcare infrastructure, presence of major market players, and higher adoption of new pharmacological treatments for eye disorders. The U.S. displays the highest uptake of innovative ophthalmic drugs in North America.

Key players related content:

Key players operating in the ophthalmic drugs market include Abbvie Inc. (Allergan Plc), Alcon, Inc., Novartis AG, Pfizer Inc., Bausch & Lomb Incorporated, F. Hoffmann-LA Roche Ltd. (Genentech, Inc.), among others. Major players are focusing on new product launches and geographical expansion to strengthen their market position.

Explore more information on this topic, Please visit @

https://www.rapidwebwire.com/ophthalmic-drugs-market-propelled-by-aging-population-growth